Ricky Sun, Ph.D., M.B.A.

Dr. Sun has served as a member of Savara’s Board of Directors since December 2019. Dr. Sun is a Managing Director at Bain Capital Life Sciences, LP and serves on the Board of Directors of Arcutis Biotherapeutics and Annexon Biosciences. Prior to joining Bain Capital, Dr. Sun was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, he was a Vice President at BlackRock as a member of the Fundamental Equity division of the Alpha Strategies Group and Senior Analyst for the fundamental large cap growth equity team where he covered the healthcare sector. Prior to BlackRock, Dr. Sun was a Senior Healthcare Analyst at Citadel and Alyeska Investment Group. He also worked as a pharmaceutical equity Research Analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. He began his career as a Senior Scientist at Ironwood Pharmaceuticals, where he was involved in the discovery and development of Linzess, a drug for irritable bowel syndrome. Dr. Sun holds a Ph.D. in chemistry and chemical biology from Harvard University and was an NIH post-doctoral fellow in biological chemistry and molecular pharmacology at Harvard Medical School. He also received an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry.